Explore the evolution of IgA nephropathy treatment, highlighting new guidelines and targeted therapies that improve patient ...

Explore the evolution of IgA nephropathy treatment, highlighting new guidelines and targeted therapies that improve patient outcomes.

FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting ...

In the past week, Wolfe Research upgraded Vertex Pharmaceuticals from “Peer Perform” to “Outperform,” citing growing ...

Dr Gaia Coppock examines approaches to guide colleagues and patients through the quickly changing landscape of IgA ...

Medically reviewed by David Ozeri, MD IgA nephropathy is a disease that can cause scarring in the kidneys.The kidney scarring from IgA nephropathy cannot be reversed once it occurs.While IgA ...

Vera Therapeutics recently announced that the U.S. FDA accepted its Biologics License Application for atacicept in adults with IgA nephropathy under Priority Review, with a PDUFA target action date of ...

Dr Gaia Coppock comments on how collaborative care among nephrologists is transforming glomerular disease treatment.

Atacicept, a novel dual inhibitor of BAFF and APRIL, receives FDA Priority Review for IgA nephropathy treatment in adults.

Immunoglobulin A (IgA) nephropathy is an autoimmune condition that causes inflammation and damage in your kidneys, which may lead to kidney failure over time. IgA nephropathy develops when IgA builds ...